✦ LIBER ✦

T1257 Characterization of Changes of Serum Anti-Glycan Antibodies in Individual Patients Over Time in Inflammatory Bowel Disease (IBD)

✍ Scribed by Rieder, Florian; Schleder, Stephan; Wolf, Alexandra; Schirbel, Anja; Franke, Andre; Dirmeier, Andrea; Obermeier, Florian; Lopez, Rocio; Rogler, Gerhard; Dotan, Nir; Klebl, Frank

Book ID: 122901260
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 44 KB
Volume: 138
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(10)62412-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Over-time changes of Helicobacter pylori

Over-time changes of Helicobacter pylori infection rate in patients with inflammatory bowel disease

✍ Triantafillidis, John K.; Gikas, Aristofanis 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 169 KB

Impact of Antibodies to Infliximab on Cl

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

✍ Nanda, Kavinderjit S; Cheifetz, Adam S; Moss, Alan C 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 286 KB

P551 Detection of anti infliximab antibo

P551 Detection of anti infliximab antibodies in patients with inflammatory bowel disease (IBD) in the presence of infliximab by homogeneous liquid phase anti infliximab mobility shift assay

✍ Eser, A.; Primas, C.; Haunstein, S.; Lockton, S.; Wang, S.; Singh, S.; Reinisch, 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 68 KB

P302 Utility of “trough levels” determin

P302 Utility of “trough levels” determination and anti-infliximab antibodies in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters (PK) through population pharmacokinetic model

✍ Juan, G.; Alvariño, A.; Oltra, L.; Maroto, N.; Cano, N.; Ferrer, I.; Hinojosa, J 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 52 KB

Sa1289 Analysis of Clinical and Serologi

Sa1289 Analysis of Clinical and Serological Associations, and the Clinical Consequences of the Development of Human Anti-Chimeric Antibodies (HACAs), and Low Serum Infliximab (IFX) Levels in Inflammatory Bowel Disease (IBD)

✍ Sundip S. Karsan; Erica R. Cohen; Stephan R. Targan; Andrew Ippoliti; David Q. S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 95 KB